Virginia Entrepreneur and CEO of Snow Companies Brenda Snow is proud to announce the release of her upcoming book, Diagnosed: The Essential Guide to Navigating the Patient's Journey (Amplify ...
Contract Development and Manufacturing Organizations (CDMOs) enhance drug discovery by providing essential services that reduce costs and accelerate production.
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eric Green, the longtime director of the National Human Genome Research Institute, has abruptly left his role, according to two employees with knowledge of the situation and internal communications ...
The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...
Pfizer, one of the world’s largest pharmaceutical companies, has announced that David Lepoittevin will be its new country manager for Belgium and Luxembourg.
Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts ...
In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total pay increase, according (PDF) to a securities filing.
Pfizer closed at $25.60, slipping 0.43% in the latest session, outperforming broader market losses. While the S&P 500 dropped ...
4d
Zacks Investment Research on MSNPfizer (PFE) Stock Moves -0.43%: What You Should KnowThe most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...
Pfizer is ranked third among the best pharma stocks to buy according to hedge funds. The company boasts a strong oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results